The findings are from a post-hoc analysis of data from 3,861 hemodialysis patients with secondary hyperparathyroidism (SHPT) who participated in the EVOLVE Trial, in which researchers randomized subjects to receive either cinacalcet or placebo in addition to conventional therapies for chronic kidney disease-mineral bone disease.
Of the 3,861 patients, 24 experienced calciphylaxis: 6 in the cinacalcet arm and 18 in the placebo arm, a difference that translated into a significant 75% decreased risk of calciphylaxis.
The researchers, Jürgen Floege, MD, of RWTH University of Aachen, Germany, and collaborators, also found that male patients had a 67% decreased risk of calciphylaxis. Each 10 mm increment in diastolic blood pressure was associated with a significant 50% increased risk. Having had a parathyroidectomy was associated with a significant 5.8 times increased risk.